<DOC>
	<DOCNO>NCT00749684</DOCNO>
	<brief_summary>The aim observational study document efficacy tolerability high-dose interferon therapy adult participant malignant melanoma high risk relapse compare survival time relapse rate previous study ( historical control ) .</brief_summary>
	<brief_title>Efficacy Safety High-dose Interferon Alfa-2b ( Intron A® ) Adjuvant Treatment Malignant Melanoma ( Study P04083 )</brief_title>
	<detailed_description>Observational study evaluate tolerability efficacy ( vs historical control ) high-dose therapy scheme interferon-α-2b ( IntronA® ) : Adjuvant treatment interferon-α-2 demonstrated number study antiproliferative effect malignant melanoma . In case response rate 20 % could achieve dose 10 million IU 3x/week daily . Kirkwood et al . show study carry ECOG ( Eastern Cooperative Oncology Group , study . 1684 ) clear significant survival advantage versus observation group follow dose : 20 mio IU/m² interferon-α-2b ( IntronA® ) 5x/week iv course one month follow 11 month 10 mio IU/m² 3x/week sc .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male female participant Age 1870 year Malignant melanoma stage II III ( &gt; /= 1.5 mm tumor thickness , distant metastasis Malignant melanoma lymph node metastases Lymph node metastasis unknown primary tumor An excision border least 2 cm around primary tumor Therapy must start within 12 week surgery tumor/of lymph node metastases ECOG status 01 ( = Karnofsky Index &gt; /= 80 ) Laboratory parameter Hematocrit &gt; = 33 % Leukocytes &gt; = 3000/μl Thrombocytes &gt; = 100000/μl Alanine aminotransferase ( ALT ) &lt; = 2x normal value Bilirubin &lt; = 2x normal value Known allergy one medication component part Refusal part participant capable childbearing use reliable contraceptive Lactating mother Presence distant metastases Another primary tumor different histological origin correspond indication ( except relapsefree interval &gt; 5 year , tumor cervical carcinoma situ , basal cell carcinoma cutaneous squamous cell carcinoma ) Participants corticosteroid treatment treatment immunomodulating substance Preexisting psychiatric illness , particularly serious depression Prior adjuvant radio , chemo , immunotherapy Treatment investigational drug within prior 30 day Participant history include cardiac arrhythmia , cardiac insufficiency require treatment , anthracycline administration Myocardial infarction within prior year An unstable medical condition ( apart indication ) judgment investigate physician excludes participant study Psoriasis ( relative exclusion criterion , since interferon aggravate psoriasis ; decision base risk/benefit analysis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>interferon-alpha</keyword>
</DOC>